<DOC>
	<DOCNO>NCT00718315</DOCNO>
	<brief_summary>This 3 arm study compare efficacy safety three different dermatological cream design prophylaxis skin rash associate Tarceva treatment patient locally advanced metastatic non-small cell lung cancer . Eligible patient recently start Tarceva treatment randomize one 3 group , receive daily treatment Verutex , Eritex Fisiogel cream 30 day , incidence severity skin rash assess . The anticipated time study treatment &lt; 3 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Verutex ( Fusidic Acid ) , Eritex ( Erythromycin ) Fisiogel Management Tarceva-Associated Rash .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<mesh_term>Fusidic Acid</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; locally advance metastatic nonsmall cell lung cancer ( stage IIIB/IV ) ; eligible start treatment Tarceva , receive Tarceva &lt; =5 day . presence skin rash sign skin toxicity ; treatment systemic intranasal antibiotic within 7 day randomization ; treatment topical formulation within 14 day randomization ; anticancer therapy addition Tarceva .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>